Offering SPR-BLI Services - Proteins provided for free!Get your ComboX free sample to test now!
Fill out organ-on-a-chip questionnaire to win a FREE gift! Fill out organ-on-a-chip questionnaire to win a FREE gift!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
Kat. Nr. | Arten | Produktbeschreibung | Struktur | Reinheit | Merkmal |
---|---|---|---|---|---|
FGB-C52H6 | Cynomolgus | Cynomolgus FGF R2 (IIIb) protein, His Tag |
|
||
FGB-H5256 | Human | Human FGF R2 (IIIb) protein, Fc Tag (MALS verified) |
|
||
FGB-M52H5 | Mouse | Mouse FGF R2 (IIIb) protein, His Tag |
|
||
FGB-H5223 | Human | Human FGF R2 (IIIb) protein, His Tag (MALS verified) |
|
Biotinylated Human FGF-10, His,Avitag (Cat. No. FG0-H81Q7) immobilized on SA Chip can bind Human FGFR2 (IIIb), His Tag (Cat. No. FGB-H5223) with an affinity constant of 5.02 μM as determined in a SPR assay (Biacore 8K) (Routinely tested).
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Erdafitinib | 890E37NHMV; G-024; JNJ-493; JNJ-42756493; TAR-210 | Approved | Astex Pharmaceuticals Inc | Balversa | United States | Carcinoma, Transitional Cell | Janssen Biotech Inc | 2019-04-12 | Lymphoma, Non-Hodgkin; Osteosarcoma; Sarcoma, Ewing; Prostatic Neoplasms; Breast Neoplasms; Histiocytic Sarcoma; Hepatic Insufficiency; Bile Duct Neoplasms; Urologic Neoplasms; Carcinoma, Squamous Cell; Glioma; Sarcoma; Lymphoma; Carcinoma, Neuroendocrine; Neoplasms, Neuroepithelial; Carcinoma, Hepatocellular; Xanthogranuloma, Juvenile; Neuroectodermal Tumors, Primitive, Peripheral; Neoplasms, Germ Cell and Embryonal; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Medulloblastoma; Ependymoma; Bone metastases; Rhabdomyosarcoma; Hematologic Neoplasms; Carcinoma; Rhabdoid Tumor; Hepatoblastoma; Esophageal Neoplasms; Stomach Neoplasms; Solid tumours; Wilms Tumor; Neoplasms; Glioblastoma; Central Nervous System Neoplasms; Urinary Bladder Neoplasms; Prostatic Neoplasms, Castration-Resistant; Multiple Myeloma; Neuroblastoma; Histiocytosis, Langerhans-Cell | Details |
Futibatinib | TAS-120 | Approved | Taiho Pharmaceutical Co Ltd, Otsuka Pharmaceutical Co Ltd | LYTGOBI | United States | Cholangiocarcinoma | Taiho Oncology Inc | 2022-09-30 | Biliary Tract Neoplasms; Solid tumours; Bone Marrow Neoplasms; Carcinoma; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Central Nervous System Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Sarcoma; Endometrial Neoplasms; Lymphoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung | Details |
Anlotinib Dihydrochloride | AL-3818 | Approved | Advenchen Laboratories Llc, Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | 福可维 | Mainland China | Carcinoma, Non-Small-Cell Lung | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | 2018-05-08 | Glioma; Bile Duct Diseases; Peritoneal Neoplasms; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Bone Neoplasms; Urologic Neoplasms; Hepatic Insufficiency; Thyroid Neoplasms; Sarcoma, Alveolar Soft Part; Fallopian Tube Neoplasms; Nasopharyngeal Carcinoma; Lung Neoplasms; Esophageal Squamous Cell Carcinoma; Endometrial Neoplasms; Gallbladder Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Osteoma; Melanoma; Neoplasms; Ovarian Neoplasms; Drug-Related Side Effects and Adverse Reactions; Head and Neck Neoplasms; Solid tumours; Biliary Tract Neoplasms; Carcinoma, Renal Cell; Stomach Neoplasms; Thoracic Neoplasms; Esophageal Neoplasms; Leiomyosarcoma; Small Cell Lung Carcinoma; Carcinoma, Ovarian Epithelial; Lymphoma, Large B-Cell, Diffuse; Sarcoma, Synovial; Lung Diseases, Interstitial; Neuroendocrine Tumors; Liver Diseases; Sarcoma; Medullary thyroid cancer (MTC) | Details |
Pemigatinib | INCB-054828; INCB-54828; IBI-375 | Approved | Incyte Corp | Pemazyre, 伯坦, 达伯坦 | United States | Cholangiocarcinoma | Incyte Corp | 2020-04-17 | Breast Neoplasms; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Glioma; Lung Neoplasms; Lymphoma; Colitis, Ulcerative; Bile Duct Neoplasms; Colorectal Neoplasms; Urologic Neoplasms; Cholangiocarcinoma; Translocation, Genetic; Bone Marrow Neoplasms; Multiple Myeloma; Urinary Bladder Neoplasms; Glioblastoma; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Neoplasms; Myeloproliferative Disorders; Carcinoma; Carcinoma, Renal Cell; Stomach Neoplasms; Biliary Tract Neoplasms; Solid tumours | Details |
Nintedanib Esylate | BIBF-1120 | Approved | C.H. Boehringer Sohn Ag & Co. Kg | Ofev, Vargatef | United States | Idiopathic Pulmonary Fibrosis | Boehringer Ingelheim Gmbh | 2014-10-15 | Carcinoma, Squamous Cell; Sarcoma; Prostatic Neoplasms; systemic sclerosis-associated interstitial lung disease; Adenocarcinoma, Clear Cell; Colorectal Neoplasms; Peritoneal Neoplasms; Astrocytoma; Genital Neoplasms, Female; Hepatic Insufficiency; Silicosis; Gliosarcoma; Breast Neoplasms; Lung Neoplasms; Appendiceal Neoplasms; Fallopian Tube Neoplasms; Leukemia, Myeloid, Acute; Uterine Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Carcinoma, Endometrioid; Adenocarcinoma; Glioblastoma; Telangiectasia, Hereditary Hemorrhagic; Solid tumours; Radiation Pneumonitis; Esophageal Neoplasms; Rejection of lung transplantation; Carcinoma, Renal Cell; Carcinoid Tumor; Endometrial Stromal Tumors; Colonic Neoplasms; Idiopathic Pulmonary Fibrosis; Ovarian Neoplasms; Scleroderma, Systemic; Neoplasms; Small Cell Lung Carcinoma; Lung Diseases, Interstitial; Mesothelioma; Pulmonary Fibrosis; Multiple Myeloma; Asbestosis; Oligodendroglioma; Neuroendocrine Tumors | Details |
Regorafenib | DAST; BAY-73-4506 | Approved | Bayer AG | Stivarga, Resihance | United States | Colorectal Neoplasms | Bayer Healthcare Pharmaceuticals Inc | 2012-09-27 | Esophageal adenocarcinoma; Osteosarcoma; Sarcoma, Ewing; Bile Duct Neoplasms; Peritoneal Neoplasms; Bone Neoplasms; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Fallopian Tube Neoplasms; Lung Neoplasms; Thyroid Neoplasms; Sarcoma; Leukemia, Myeloid, Acute; Thymoma; Melanoma; Gastrointestinal Neoplasms; Carcinoma, Hepatocellular; Adenocarcinoma; Somatostatinoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Solid tumours; Liver Neoplasms; Carcinoid Tumor; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Islet Cell; Insulinoma; Hemangiosarcoma; Rectal Neoplasms; Carcinoma, Renal Cell; Ovarian Neoplasms; Pancreatic Neoplasms; Colonic Neoplasms; Neoplasms; Glioblastoma; Carcinoma, Transitional Cell; Glucagonoma; Carcinoma, Adenoid Cystic; Adenoma; Gastrinoma | Details |
Lenvatinib Mesylate | ER-203492-00; E-7080; MK-7902 | Approved | Eisai Co Ltd | Lenvima, Lenvima/Kisplyx, 乐卫玛, Kisplyx | United States | Thyroid Neoplasms | Eisai Inc | 2015-02-13 | Carcinoma, Adenoid Cystic; Thyroid Cancer, Papillary; Melanoma; Paraganglioma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Glioma; Lymphoma; Thyroid Neoplasms; Endometrial Neoplasms; Hepatic Insufficiency; Cholangiocarcinoma; Breast Neoplasms; Osteosarcoma; Solid tumours; Adenocarcinoma, Follicular; Liver Diseases; Neuroendocrine Tumors; Thyroid Carcinoma, Anaplastic; Kidney Diseases; Adenocarcinoma of Lung; Neoplasms; Esophageal Neoplasms; Renal Insufficiency; Carcinoma, Renal Cell; Pheochromocytoma; Ovarian Neoplasms; Liver Neoplasms; Biliary Tract Neoplasms | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Bemarituzumab | FPA-144 | Phase 3 Clinical | Five Prime Therapeutics Inc | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Digestive System Neoplasms; Carcinoma, Squamous Cell; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms | Details |
Infigratinib | BGJ-398; NVP-BGJ398 | Phase 3 Clinical | Novartis Pharma Ag | Papillomavirus Infections; Uterine Cervical Neoplasms; Adenocarcinoma; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Glioma; Oropharyngeal Neoplasms; Gastrointestinal Stromal Tumors; Breast Neoplasms; Cholangiocarcinoma; Urinary Bladder Neoplasms; Central Nervous System Neoplasms; Glioblastoma; Solid tumours; Nasopharyngeal Neoplasms; Colonic Neoplasms; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Achondroplasia; Rectal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Esophageal Neoplasms; Hematologic Neoplasms; Biliary Tract Neoplasms | Details |
Rogaratinib | BAY-1163877 | Phase 3 Clinical | Bayer AG | Solid tumours; Carcinoma, Transitional Cell; Neoplasms; Urinary Bladder Neoplasms; Sarcoma; Breast Neoplasms; Gastrointestinal Stromal Tumors; Carcinoma, Non-Small-Cell Lung | Details |
Fexagratinib | AZD4547; AZD-4547; ABSK-091; ABSK091 | Phase 3 Clinical | Astrazeneca Plc | Lung Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal adenocarcinoma; Endometrial Neoplasms; Lymphoma; Uterine Neoplasms; Multiple Myeloma; Glioma; Thyroid Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung; Foodborne Diseases; Uterine Cervical Neoplasms; Melanoma; Adenocarcinoma; Stomach Neoplasms; Liver Neoplasms; Ovarian Neoplasms; Head and Neck Neoplasms; Hematologic Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Rectal Neoplasms; Carcinoma, Renal Cell; Solid tumours; Gastrointestinal Diseases; Neoplasms; Carcinoma, Transitional Cell; Skin Neoplasms; Colonic Neoplasms; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Urinary Bladder Neoplasms | Details |
CPL-304110 | CPL-304110; CPL-304-110 | Phase 1 Clinical | Celon Pharma Sa | Stomach Neoplasms; Urinary Bladder Neoplasms; Sarcoma; Cholangiocarcinoma; Endometrial Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung | Details |
Efruxifermin | AKR-001; AMG-876; EFX; Fc-FGF21(RGE) | Phase 3 Clinical | Amgen Inc | Non-alcoholic Fatty Liver Disease; Diabetes Mellitus | Details |
Lirafugratinib | RLY-4008 | Phase 2 Clinical | Relay Therapeutics Inc | Cholangiocarcinoma; Translocation, Genetic | Details |
Tasurgratinib | E-7090 | Phase 2 Clinical | Eisai Co Ltd | Biliary Tract Neoplasms; Solid tumours; Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Hepatic Insufficiency | Details |
LY-2874455 | LY-2874455 | Phase 1 Clinical | Eli Lilly And Company | Neoplasms; Leukemia, Myeloid, Acute | Details |
Lucitanib | S-80881; AL-3810; CO-3810; E-3810; S-80881-2 | Phase 3 Clinical | Advenchen Laboratories Nanjing Ltd | Solid tumours; Stomach Neoplasms; Small Cell Lung Carcinoma; Nasopharyngeal Carcinoma; Breast Neoplasms; Colorectal Neoplasms; Genital Neoplasms, Female; Thymus Neoplasms; Lung Neoplasms; Carcinoma, Small Cell; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | Details |
ABSK-121 | ABSK121-NX; ABSK121 | Phase 1 Clinical | ABbisko Therapeutics Co Ltd | Solid tumours | Details |
Nintedanib Solution for Inhalation | AP02; AP-02 | Phase 1 Clinical | Avalyn Pharma Inc | Idiopathic Pulmonary Fibrosis | Details |
HMPL-453 | HMPL-453 | Phase 2 Clinical | Hutchison Medipharma Ltd | Solid tumours; Biliary Tract Neoplasms; Neoplasms, Mesothelial; Mesothelioma; Cholangiocarcinoma | Details |
TT-00434 | TT-00434 | Phase 1 Clinical | TransThera Sciences (Nanjing) Inc | Solid tumours; Urinary Bladder Neoplasms | Details |
TYRA-200 | TYRA200; TYRA-200 | Phase 1 Clinical | Tyra Biosciences Inc | Biliary Tract Neoplasms; Solid tumours; Cholangiocarcinoma; Bile Duct Neoplasms | Details |
Gunagratinib | ICP-192 | Phase 2 Clinical | Beijing Tiancheng Pharmaceutical Technology Co Ltd | Solid tumours; Biliary Tract Neoplasms; Head and Neck Neoplasms; Stomach Neoplasms; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Cholangiocarcinoma; Lung Neoplasms | Details |
BPI-17509 | BPI-17509 | Phase 1 Clinical | Betta Pharmaceuticals Co Ltd | Solid tumours | Details |
KIN-3248 | KIN-3248; KIN-003 | Phase 1 Clinical | Kinnate Biopharma Inc | Solid tumours; Neoplasms; Carcinoma, Transitional Cell; Cholangiocarcinoma | Details |
Derazantinib | ARQ-087.2HCl; AQ-14741087; ARQ-087; BAL-087 | Phase 2 Clinical | Arqule Inc | Biliary Tract Neoplasms; Solid tumours; Stomach Neoplasms; Carcinoma, Transitional Cell; Cholangiocarcinoma; Urogenital Neoplasms; Carcinoma, Hepatocellular | Details |
Sprifermin | rhFGF-18; trFGF-18; FGF-18; zFGF-5; Zfgf5; AS-902330 | Phase 2 Clinical | Zymogenetics Inc | Cartilage Diseases; Knee Injuries; Osteoarthritis, Knee | Details |
Zoligratinib | CH-5183284; FF-284; Debio-1347 | Phase 2 Clinical | Chugai Pharmaceutical Co Ltd | Solid tumours; Breast Neoplasms | Details |
ODM-203 | ODM-203 | Phase 1 Clinical | Orion Corp | Solid tumours | Details |
Alofanib | RPT-835 | Phase 1 Clinical | Russian Pharmaceutical Technologies Llc | Stomach Neoplasms | Details |
HH185 | 3D-185; 3-D185; HH-185; 3D185 | Phase 2 Clinical | ShangHai HaiHe Biopharma Co Ltd, Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences, Shanghai Medicilon Inc | Solid tumours; Cholangiocarcinoma | Details |
ABSK-061 | ABSK061 | Phase 1 Clinical | ABbisko Therapeutics Co Ltd | Solid tumours | Details |
SC-0011 | SC-0011 | Phase 1 Clinical | Shijiazhuang Zhikang Hongren New Drug Development Co Ltd | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
This web search service is supported by Google Inc.